VCYT Quote, Financials, Valuation and Earnings

Fonar has a net margin of 4.31% compared to Veracyte's net margin of 7.87%. Veracyte's return on equity of 2.14% beat Fonar's return on equity of 4.95%.

Veracyte has a consensus price target of $42.20, signalling upside risk potential of 30.93%. On the other hand Fonar has an analysts' consensus of -- which suggests that it could fall by --. Given that Veracyte has higher upside potential than Fonar, analysts believe Veracyte is more attractive than Fonar.

Veracyte has a beta of 2.032, which suggesting that the stock is 103.174% more volatile than S&P 500. In comparison Fonar has a beta of 1.167, suggesting its more volatile than the S&P 500 by 16.736%.

Veracyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Fonar offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Veracyte pays -- of its earnings as a dividend. Fonar pays out -- of its earnings as a dividend.

Veracyte quarterly revenues are $118.6M, which are larger than Fonar quarterly revenues of $25M. Veracyte's net income of $5.1M is higher than Fonar's net income of $2M. Notably, Veracyte's price-to-earnings ratio is 107.43x while Fonar's PE ratio is 10.45x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Veracyte is 5.62x versus 0.76x for Fonar. Usually stocks with elevated PS ratios are considered overvalued.

OncoCyte has a net margin of 4.31% compared to Veracyte's net margin of -2255.11%. Veracyte's return on equity of 2.14% beat OncoCyte's return on equity of -581.11%.

Veracyte has a consensus price target of $42.20, signalling upside risk potential of 30.93%. On the other hand OncoCyte has an analysts' consensus of $4.42 which suggests that it could grow by 28.39%. Given that Veracyte has higher upside potential than OncoCyte, analysts believe Veracyte is more attractive than OncoCyte.

Veracyte has a beta of 2.032, which suggesting that the stock is 103.174% more volatile than S&P 500. In comparison OncoCyte has a beta of 0.973, suggesting its less volatile than the S&P 500 by 2.709%.

Veracyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. OncoCyte offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Veracyte pays -- of its earnings as a dividend. OncoCyte pays out -- of its earnings as a dividend.

Veracyte quarterly revenues are $118.6M, which are larger than OncoCyte quarterly revenues of $1.5M. Veracyte's net income of $5.1M is higher than OncoCyte's net income of -$33.5M. Notably, Veracyte's price-to-earnings ratio is 107.43x while OncoCyte's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Veracyte is 5.62x versus 23.89x for OncoCyte. Usually stocks with elevated PS ratios are considered overvalued.

ProPhase Labs has a net margin of 4.31% compared to Veracyte's net margin of -209.38%. Veracyte's return on equity of 2.14% beat ProPhase Labs's return on equity of -59.59%.

Veracyte has a consensus price target of $42.20, signalling upside risk potential of 30.93%. On the other hand ProPhase Labs has an analysts' consensus of $13.80 which suggests that it could grow by 3640.85%. Given that ProPhase Labs has higher upside potential than Veracyte, analysts believe ProPhase Labs is more attractive than Veracyte.

Veracyte has a beta of 2.032, which suggesting that the stock is 103.174% more volatile than S&P 500. In comparison ProPhase Labs has a beta of -0.562, suggesting its less volatile than the S&P 500 by 156.182%.

Veracyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ProPhase Labs offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Veracyte pays -- of its earnings as a dividend. ProPhase Labs pays out -- of its earnings as a dividend.

Veracyte quarterly revenues are $118.6M, which are larger than ProPhase Labs quarterly revenues of $3.1M. Veracyte's net income of $5.1M is higher than ProPhase Labs's net income of -$6.6M. Notably, Veracyte's price-to-earnings ratio is 107.43x while ProPhase Labs's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Veracyte is 5.62x versus 1.12x for ProPhase Labs. Usually stocks with elevated PS ratios are considered overvalued.

XWELL has a net margin of 4.31% compared to Veracyte's net margin of -56.4%. Veracyte's return on equity of 2.14% beat XWELL's return on equity of -71.82%.

Veracyte has a consensus price target of $42.20, signalling upside risk potential of 30.93%. On the other hand XWELL has an analysts' consensus of -- which suggests that it could grow by 800.79%. Given that XWELL has higher upside potential than Veracyte, analysts believe XWELL is more attractive than Veracyte.

Veracyte has a beta of 2.032, which suggesting that the stock is 103.174% more volatile than S&P 500. In comparison XWELL has a beta of 2.106, suggesting its more volatile than the S&P 500 by 110.579%.

Veracyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. XWELL offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Veracyte pays -- of its earnings as a dividend. XWELL pays out -- of its earnings as a dividend.

Veracyte quarterly revenues are $118.6M, which are larger than XWELL quarterly revenues of $8.4M. Veracyte's net income of $5.1M is higher than XWELL's net income of -$4.8M. Notably, Veracyte's price-to-earnings ratio is 107.43x while XWELL's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Veracyte is 5.62x versus 0.11x for XWELL. Usually stocks with elevated PS ratios are considered overvalued.